Study on the diagnostic value of serum pepsinogen and gastrin-17 in gastric cancer and atrophic gastritis

doi:10.3877/cma.j.issn.2095-5820.2019.04.006

Abstract

Abstract:

Objective

To investigate the level changes and clinical value of serum pepsinogen (PG) and gastrin-17 (Gastrin-17) in non-atrophic gastritis, atrophic gastritis and gastric cancer.

Method

Pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17) and the PGⅠ/PGⅡ (PGR) levels were measured in 37 patients with non-atrophic gastritis, 37 patients with atrophic gastritis and 65 patients with gastric cancer by enzyme-linked immunosorbent assay.

Results

The PGⅠand PGR in the atrophic gastritis group were significantly lower than those in the non-atrophic gastritis group (P<0.05). The PGⅠand PGR levels in the gastric cancer group were significantly lower than those in non-atrophic gastritis group and atrophic gastritis group (P<0.05). The level of PGⅡ in the gastric cancer group was significantly higher than that in the non-atrophic gastritis group (P<0.05). The G-17 in the gastric cancer group was significantly higher than that that in the atrophic gastritis and non-atrophic gastritis group (P<0.05). The G-17 in the gastric antrum cancer group was significantly higher than that in the gastric body cancer group (P<0.05).

Conclusions

Pepsinogen and gastrin can be used as serological markers for screening atrophic gastritis and gastric cancer. Serum gastrin-17 has great clinical value in distinguishing gastric antrum and gastric body cancer.

Key words: Pepsinogen, Stomach neoplasms, Atrophic gastritis, Gastrin-17

Yunfei An, Fei Ding, Bei Cai, Wenling Zhao, Jing Hu, Zhuochun Huang, Lixin Li. Study on the diagnostic value of serum pepsinogen and gastrin-17 in gastric cancer and atrophic gastritis[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(04): 214-218.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2019.04.006

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2019/V07/I04/214

Figures/Tables 7

References 15

1	Samlof IM, Varis K, Ihamaki T, et a1. Relationships among serum pepsinogen I,serum pepsinogen Ⅱ, and gastric mueosal histology. A study in relatives of patients with pernicious anemia[J]. Gastroenterology, 1982,83(1Pt2):204-209.
2	刘慧杰，高华，董明，等. 胃蛋白酶原C基因多态与胃癌遗传易感性的相关研究[J]. 中华医学杂志, 2001,81(15):947-948.
3	Shafaghi A, Mansour-Ghanaei F, Joukar F, et al. Serum gastrin and the pepsinogen Ⅰ/Ⅱ ratio as markers for diagnosis of premalignant gastric lesions[J]. Asian Pac J Cancer Prev, 2014,14(6):3931-3936.
4	Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000,50(1):7-33.
5	Watson SA, Grabowska AM, E1-Zaatari M, et a1. Gastrin-active participant or bystander in gastric carcinogenesis[J]. Nat Rev Cancer, 2006,6(12):936-946.
6	Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells[J]. Nat Rev Cancer, 2005,5(3):223-231.
7	Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan[J]. J Gastroenterol, 2007,42(1):1-15.
8	Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer[J]. Gastric Cancer, 2009,12(2):79-87.
9	Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelineson gastric cancer prevention[J]. J Gastroenterol Hepatol, 2008,23(3):351-365.
10	Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infectionand the development of gastric cancer[J]. N Engl J Med, 2001,345(11):784-789.
11	Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication toprevent gastric cancer in a high-riskregion of China: a randomizedcontrolled trial[J]. JAMA, 2004,291(2):187-194.
12	王雪华，曹燕，张剑宏，等. 血清胃蛋白酶原联合胃泌素测定在胃癌及萎缩性胃炎中的诊断价值[J/CD]. 中华临床医师杂志(电子版), 2015,5(9):1824-1827.
13	朱春平，赵建业，申晓军，等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志, 2017,34(1):19-23.
14	张洁，刘怡菁，王震华. 血清胃蛋白酶原Ⅰ、Ⅱ及其比值诊断效能评价[J]. 临床研究, 2015,6(16):860-863.
15	马颖杰，曹邦伟，李琴，等. 胃癌患者及其化疗后胃蛋白酶原与胃泌素变化的临床意义[J]. 临床和实验医学杂志, 2014,13(3):186-189.

组别	n	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G-17(pmol/L)
非萎缩性胃炎组	37	133.08(117.15~146.32)	9.47(5.65~12.31)	14.15(9.84~21.50)	5.44(2.15~8.31)
萎缩性胃炎组	37	75.20^a(57.96~93.66)	12.83(7.87~16.10)	5.50^a(4.07~10.10)	1.58(0.92~6.00)
胃癌组	65	55.74^ab(31.01~86.00)	14.27^a(8.99~26.24)	3.25^ab(1.77~4.68)	9.94^ab(3.59~22.58)

组别	n	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G-17(pmol/L)
非萎缩性胃炎组	37	133.08(117.15~146.32)	9.47(5.65~12.31)	14.15(9.84~21.50)	5.44(2.15~8.31)
萎缩性胃炎组	37	75.20^a(57.96~93.66)	12.83(7.87~16.10)	5.50^a(4.07~10.10)	1.58(0.92~6.00)
胃癌组	65	55.74^ab(31.01~86.00)	14.27^a(8.99~26.24)	3.25^ab(1.77~4.68)	9.94^ab(3.59~22.58)

组别	n	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G-17(pmol/L)
单纯萎缩	15	65.74(61.53~86.28)	13.89(7.06~15.85)	5.91(4.44~10.25)	1.33(0.01~4.15)
萎缩伴肠化	22	76.38(49.87~104.36)	12.67(8.20~16.39)	5.41(3.56~10.34)	2.85(1.09~6.82)

组别	n	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G-17(pmol/L)
单纯萎缩	15	65.74(61.53~86.28)	13.89(7.06~15.85)	5.91(4.44~10.25)	1.33(0.01~4.15)
萎缩伴肠化	22	76.38(49.87~104.36)	12.67(8.20~16.39)	5.41(3.56~10.34)	2.85(1.09~6.82)

组别	n	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G-17(pmol/L)
胃窦	32	47.91(33.56~74.18)	13.16(8.90~24.60)	3.09(2.08~5.20)	4.97(2.64~9.55)
胃体	21	56.50(24.11~88.87)	18.33(11.40~27.48)	3.26(1.34~4.41)	22.20^a(12.12~33.65)

Please choose a citation manager

Content to export